Another multi-center, randomized and positive-controlled, phase III clinical trial recruited patients with GC/EGJC identified as PD-L1 (+) who were previously untreated in order to examine the efficacy of pembrolizumab as monotherapy or in combination with chemotherapy (39). Here, CD274 is linked to gastric cancer.